secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2024-10-04T23:59:59+00:00
Accession:  0000950170-24-112930
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics receives Nasdaq delisting notice; plans to appeal
--------------------------------------------------------------------

- Received Nasdaq delisting determination on Oct 1, 2024 for non-compliance with $2.5M stockholders' equity requirement.
- Company intends to request hearing by Oct 8, 2024; hearing automatically stays suspension.
- Expects to regain compliance upon closing pending merger with Peak Bio, Inc.
- No assurance of success; shares at risk of suspension if appeal fails.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024112930/0000950170-24-112930-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024112930/aktx-20241001.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-112930

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer